SCHEMBL3532956

SCHEMBL3532956

Cn1c(C2CC2)cc(=O)n1-c1ccccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.42
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HCAR1 Q9BXC0 1/20 0.38
MGLL Q99685 1/20 0.38
NOTUM Q6P988 1/20 0.37
NOX4 Q9NPH5 1/20 0.36
BCL2A1 Q16548 1/20 0.36
ADRA1D P25100 4/20 0.36
ADRA1A P35348 4/20 0.36
ADRA1B P35368 4/20 0.36
MEN1 O00255 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALOX5 P09917 1/20 0.36
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3529498 0.88 DRD2 (0.42) NOTUMBCL2A1
SCHEMBL3535467 0.85 MEN1 (0.41) HSD11B1ALDH1A1MAPTSMN1; SMN2MGLL
SCHEMBL3533770 0.85 MAPT (0.41) ALDH1A1KDM4EMAPTSMN1; SMN2MGLL
SCHEMBL3537437 0.84 LMNA (0.40) ALDH1A1MAPTMGLLMEN1KMT2A
SCHEMBL3528186 0.84 HSD11B1 (0.45) HSD11B1ALDH1A1MAPTNOTUMADRA1D
SCHEMBL3529348 0.81 MAPT (0.42) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL3527587 0.81 MGLL (0.42) ALDH1A1KDM4EMAPTMGLLADRA1D
SCHEMBL3532454 0.81 ALDH1A1 (0.38) HSD11B1ALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL3533292 0.80 HSD11B1 (0.46) HSD11B1ALDH1A1KDM4EMAPTHCAR1
SCHEMBL3535423 0.80 DRD2 (0.40) HSD11B1ALDH1A1SMN1; SMN2ADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652057-B2 Pyrazolones as 11b-HSD1 inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US disclosed
EP-1924562-A2 PYRAZOLONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP disclosed
WO-2007025880-A2 PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes HSD11B1, HSD17B1, HSD17B7 HSD11B1 1/4885ALDH1A1 105/4885KDM4E 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.